Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV000635853 | SCV000757278 | likely pathogenic | Familial cancer of breast | 2017-10-28 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant is expected to disrupt a portion of the C-terminal region of the CHEK2 protein containing the nuclear localization signal (NLS) (residues Pro515-Pro522). Although functional studies have not been performed for this particular variant, disruption of the NLS likely impairs CHEK2 function, as variants within the NLS result in CHEK2 mislocalization to the cytoplasm (PMID: 12909615, 18004398, 24879340). This suggests that disruption of this region of the CHEK2 protein is causative of disease. This variant has not been reported in the literature in individuals with CHEK2-related disease. This variant is not present in population databases (ExAC no frequency). This sequence change results in a premature translational stop signal in the CHEK2 gene (p.Ser516Phefs*3). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 28 amino acids of the CHEK2 protein. |